| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.0064 | 0.9 |